These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Plafibride treatment of hyperlipidemias type II and IV]. Soler J, Vinzia C, Gómez JM, Morató J. Med Clin (Barc); 1984 May 19; 82(19):840-2. PubMed ID: 6738212 [No Abstract] [Full Text] [Related]
7. [Comparison of the lipid-lowering agents clofibrate and bezafibrate in patients with hyperlipoproteinemias IIa and IIb]. Kokot F, Szczechowska E. Z Gesamte Inn Med; 1981 Jul 01; 36(13):454-7. PubMed ID: 7025475 [Abstract] [Full Text] [Related]
8. [A comparison of bezafibrate and clofibrate in type II B and type IV hyperlipoproteinemia]. Bolzano K, Krempler F, Schellenberg B, Schlierf G. Acta Med Austriaca; 1979 Jul 01; 6(3):90-4. PubMed ID: 547652 [Abstract] [Full Text] [Related]
9. Changes in lipids and lipoproteins in patients with hyperlipidemia type IIb, IV and V treated with different lipid lowering drugs. Hutt V, Wechsler JG, Klör HU, Ditschuneit H. Artery; 1980 Jul 01; 8(2):113-9. PubMed ID: 7458676 [Abstract] [Full Text] [Related]
10. [Efficacy of bezafibrate and fenofibrate on elevated blood lipids in HLP type IIa, IIb and IV]. Schwartzkopff W, Luley C, Scheffler W, Lehmann-Leo W, Schilling A, Wegscheider K. Med Welt; 1982 Apr 30; 33(17):631-7. PubMed ID: 7098826 [No Abstract] [Full Text] [Related]
11. Effect of bezafibrate on the high-density lipoprotein subfractions HDL2 and HDL3 in primary hyperlipoproteinemia type IV. Schwandt P, Weisweiler P. Artery; 1980 Apr 30; 7(6):464-70. PubMed ID: 7236016 [Abstract] [Full Text] [Related]
12. Pirifibrate in the treatment of hyperlipoproteinemia: types IIa, IIb, and IV. Lopez Rodriguez J, Martorell J. Clin Ther; 1980 Apr 30; 3(4):234-41. PubMed ID: 7273061 [Abstract] [Full Text] [Related]
14. Lipids and lipoproteins in hyperlipidemia type IIa during treatment with different lipid lowering drugs. Wechsler JG, Hutt V, Klör HU, Ditschuneit H. Artery; 1980 Apr 30; 8(6):519-29. PubMed ID: 7259531 [Abstract] [Full Text] [Related]
16. [Controlled clinical trial of a new drug (plafibride) for the treatment of hyperlipoproteinemia type IV (author's transl)]. Ferreira Montero IJ, Gutiérrez Martín M, del Río Ligorit A, Casasnovas Lenguas JA, Cornudella Lacasa R. Med Clin (Barc); 1982 May 01; 78(9):380-5. PubMed ID: 7047926 [No Abstract] [Full Text] [Related]
17. The effect of etofibrate retard, bezafibrate and procetofen. Luley C, Schwartzkopff W, Schilling A, Calder D, Scheffler W. Artery; 1980 May 01; 8(2):128-33. PubMed ID: 7458677 [Abstract] [Full Text] [Related]
18. [Effect of clofibric acid on fatty acid metabolism in HLP patients in the 2d half of life]. Reuter W. Z Alternsforsch; 1982 May 01; 37(6):409-16. PubMed ID: 7164480 [Abstract] [Full Text] [Related]
19. [Double-blind study of the therapeutic activity of a new hypolipemic drug: etofibrate]. Altomonte L, Mingrone G, Negrini A, De Cunto F, Greco AV. Clin Ter; 1981 Jan 15; 96(1):31-8. PubMed ID: 7016409 [No Abstract] [Full Text] [Related]
20. [Bile lipid composition in subjects with blood lipid disorders (types II and IV). Effect of a new hypolipemic drug (Etofibrate)]. Altomonte L, Mingrone G, Ghirlanda G, Manna R, Rebuzzi A, Pala MA, Greco AV. Minerva Med; 1980 Feb 11; 71(4):273-8. PubMed ID: 7354946 [Abstract] [Full Text] [Related] Page: [Next] [New Search]